IS6869A - Bætt aðferð við að framleiða hreint ondansetrónhýdróklóríðdíhýdrat - Google Patents
Bætt aðferð við að framleiða hreint ondansetrónhýdróklóríðdíhýdratInfo
- Publication number
- IS6869A IS6869A IS6869A IS6869A IS6869A IS 6869 A IS6869 A IS 6869A IS 6869 A IS6869 A IS 6869A IS 6869 A IS6869 A IS 6869A IS 6869 A IS6869 A IS 6869A
- Authority
- IS
- Iceland
- Prior art keywords
- improved method
- producing pure
- hydrochloride dihydrate
- ondansetron hydrochloride
- pure ondansetron
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26105201P | 2001-01-11 | 2001-01-11 | |
PCT/US2002/000853 WO2002055492A2 (en) | 2001-01-11 | 2002-01-11 | An improved process for preparing pure ondansetron hydrochloride dihydrate |
Publications (1)
Publication Number | Publication Date |
---|---|
IS6869A true IS6869A (is) | 2003-07-08 |
Family
ID=22991757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6869A IS6869A (is) | 2001-01-11 | 2003-07-08 | Bætt aðferð við að framleiða hreint ondansetrónhýdróklóríðdíhýdrat |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1355881A4 (hu) |
JP (1) | JP2004526692A (hu) |
KR (3) | KR20060113792A (hu) |
CN (2) | CN1496350A (hu) |
AU (1) | AU2002236753B2 (hu) |
CA (1) | CA2433720A1 (hu) |
CZ (1) | CZ20032090A3 (hu) |
DE (1) | DE02703115T1 (hu) |
ES (1) | ES2219201T1 (hu) |
HR (1) | HRP20030631A2 (hu) |
HU (1) | HUP0400767A2 (hu) |
IL (1) | IL156835A0 (hu) |
IS (1) | IS6869A (hu) |
MX (1) | MXPA03006215A (hu) |
NO (1) | NO20033147L (hu) |
PL (1) | PL368837A1 (hu) |
SK (1) | SK9892003A3 (hu) |
TR (1) | TR200401460T3 (hu) |
WO (1) | WO2002055492A2 (hu) |
YU (1) | YU56103A (hu) |
ZA (1) | ZA200305338B (hu) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098345B2 (en) | 2002-04-29 | 2006-08-29 | TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one |
HU225885B1 (en) * | 2002-10-17 | 2007-11-28 | Richter Gedeon Nyrt | Process for producing ondansetron hydrochlorid dihydrate of high purity |
FI6164U1 (fi) * | 2003-01-09 | 2004-03-15 | Synthon Bv | Ondansetronmuotoja |
GB2398071B (en) * | 2003-01-24 | 2006-06-07 | Synthon Bv | Process for making ondansetron and intermediate thereof |
US7696356B2 (en) | 2004-08-17 | 2010-04-13 | Taro Pharmaceutical Industries Limited | Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom |
EP1828141A4 (en) * | 2004-10-26 | 2009-04-01 | Ipca Lab Ltd | STAINING METHOD FOR PREPARING THE ANTIEMETIC 1,2,3,9-TETRAHYDRO-9-METHYL-3 - [(2-METHYL) -1H-IMIDAZOLE-1-YL) METHYL] -4H-CARBAZOLE-4-ON |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4695578A (en) * | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
GB8630071D0 (en) * | 1986-12-17 | 1987-01-28 | Glaxo Group Ltd | Medicaments |
EP1339707A2 (en) * | 2000-10-30 | 2003-09-03 | Teva Pharmaceutical Industries Ltd. | Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation |
-
2002
- 2002-01-11 IL IL15683502A patent/IL156835A0/xx unknown
- 2002-01-11 JP JP2002556165A patent/JP2004526692A/ja active Pending
- 2002-01-11 YU YU56103A patent/YU56103A/sh unknown
- 2002-01-11 EP EP02703115A patent/EP1355881A4/en not_active Withdrawn
- 2002-01-11 SK SK989-2003A patent/SK9892003A3/sk not_active Application Discontinuation
- 2002-01-11 AU AU2002236753A patent/AU2002236753B2/en not_active Expired - Fee Related
- 2002-01-11 CZ CZ20032090A patent/CZ20032090A3/cs unknown
- 2002-01-11 KR KR1020067020069A patent/KR20060113792A/ko not_active Application Discontinuation
- 2002-01-11 KR KR10-2003-7009221A patent/KR20030068583A/ko active IP Right Grant
- 2002-01-11 CA CA002433720A patent/CA2433720A1/en not_active Abandoned
- 2002-01-11 PL PL02368837A patent/PL368837A1/xx not_active Application Discontinuation
- 2002-01-11 KR KR1020077010146A patent/KR20070054749A/ko not_active Application Discontinuation
- 2002-01-11 HU HU0400767A patent/HUP0400767A2/hu unknown
- 2002-01-11 CN CNA028062019A patent/CN1496350A/zh active Pending
- 2002-01-11 ZA ZA200305338A patent/ZA200305338B/xx unknown
- 2002-01-11 WO PCT/US2002/000853 patent/WO2002055492A2/en active Application Filing
- 2002-01-11 MX MXPA03006215A patent/MXPA03006215A/es unknown
- 2002-01-11 TR TR2004/01460T patent/TR200401460T3/xx unknown
- 2002-01-11 DE DE02703115T patent/DE02703115T1/de active Pending
- 2002-01-11 ES ES02703115T patent/ES2219201T1/es active Pending
- 2002-01-11 CN CNA2006101667179A patent/CN101045704A/zh active Pending
-
2003
- 2003-07-08 IS IS6869A patent/IS6869A/is unknown
- 2003-07-09 NO NO20033147A patent/NO20033147L/no not_active Application Discontinuation
- 2003-08-06 HR HR20030631A patent/HRP20030631A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN101045704A (zh) | 2007-10-03 |
NO20033147D0 (no) | 2003-07-09 |
WO2002055492A2 (en) | 2002-07-18 |
CZ20032090A3 (cs) | 2004-08-18 |
PL368837A1 (en) | 2005-04-04 |
EP1355881A4 (en) | 2004-03-31 |
NO20033147L (no) | 2003-09-02 |
MXPA03006215A (es) | 2005-02-17 |
HRP20030631A2 (en) | 2005-06-30 |
AU2002236753B2 (en) | 2007-06-28 |
EP1355881A2 (en) | 2003-10-29 |
YU56103A (sh) | 2006-05-25 |
IL156835A0 (en) | 2004-02-08 |
KR20030068583A (ko) | 2003-08-21 |
KR20070054749A (ko) | 2007-05-29 |
CN1496350A (zh) | 2004-05-12 |
JP2004526692A (ja) | 2004-09-02 |
HUP0400767A2 (hu) | 2004-07-28 |
TR200401460T3 (hu) | 2004-08-23 |
ZA200305338B (en) | 2004-07-12 |
CA2433720A1 (en) | 2002-07-18 |
SK9892003A3 (en) | 2004-05-04 |
WO2002055492A3 (en) | 2003-02-13 |
KR20060113792A (ko) | 2006-11-02 |
ES2219201T1 (es) | 2004-12-01 |
DE02703115T1 (de) | 2004-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60205413D1 (de) | Herstellungsverfahren | |
FR15C0028I2 (fr) | Fabrication de tiacumicine | |
EE200300420A (et) | Vormitiste tootmise meetod | |
PL357927A1 (en) | Method of obtaining trimethylpropane | |
BR0214746B1 (pt) | mÉtodo de produzir embreagem unidirecional | |
NO20033267L (no) | Fremgangsmåter for öket produksjon av av pantothenat | |
DE60235767D1 (de) | Sublimationsmuster-giessverfahren | |
PL355161A1 (en) | Method of manufacture | |
ITTO20020964A1 (it) | Metodo di fabbricazione di un albero a gomiti per un | |
IL156791A0 (en) | Manufacturing method of combined vaccine | |
EP1428932A4 (en) | PROCESS FOR MANUFACTURING MOLDINGS | |
IS7069A (is) | Aðferð til að framleiða zaleplon | |
IS6869A (is) | Bætt aðferð við að framleiða hreint ondansetrónhýdróklóríðdíhýdrat | |
MXPA03007379A (es) | Metodo de manufactura de forma de concreto. | |
FI20010472A0 (fi) | Menetelmä alfa-pineenin hydraamiseksi | |
DE60207451D1 (de) | Produktionsverfahren | |
PL352959A1 (en) | Method of obtaining derivatives of taxane | |
ITMI20010729A0 (it) | Metodo per la preparazione di manto di usura | |
PL356317A1 (en) | Method of obtaining alkanosulphonylpyridines | |
GB0104109D0 (en) | Method of manufacture | |
SI1349572T1 (sl) | Postopek izdelave kombinirane vakcine | |
SE0104249D0 (sv) | Method of treatment | |
EE00274U1 (et) | Siirupi valmistamismeetod | |
PL347523A1 (en) | Method of obtaining 11alpha-hydroxy-1-dehydrotestosterone | |
PL347522A1 (en) | Method of obtaining 14alpha-hydroxy-1-dehydrostesterone |